drugset / Trial / NCT05146999

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

NCT05146999

Phase 3 Completed 132 enrolled Galderma R&D
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines

Timeline

Start
2022-05-09
Primary completion
2022-10-28
Completion
2023-09-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin Protein / enzyme biologic

Indications

No indication recorded.